Dr Nadav Ben-Haim
Commercialisation Case Manager
Email: [email protected]
Biography
I am an experienced patent specialist and innovation manager with a strong background in intellectual property (IP) management and research commercialisation. I managed IP for a large academic hospital, a multinational pharmaceutical company, and several start-up ventures. Passionate about translating research into real-world applications, I have been instrumental in spinning out multiple research projects into industry. Additionally, I served as the commercial lead for the MindSave project at the University of Galway, an Enterprise Ireland-funded initiative that developed a ground-breaking vascular implant for treating stroke.
I hold a PhD in Life Sciences from the University of Lausanne, an MBA from HFU German University of Applied Sciences, a Bachelor's and Master’s degrees in Biomedical Sciences from the Hebrew University, and a Postgraduate Diploma in BioInnovation from the University of Galway.
Currently, I am the Life Sciences and Business Commercialisation Case Manager at the Innovation and Commercialisation Office at SETU. In this role, I oversee and expand SETU’s IP portfolio, with a focus on life sciences, biotechnology, healthcare technologies, and business innovation. I work to ensure the successful commercialisation and strategic development of IP assets, fostering innovation and supporting business growth.
I enjoy collaborating with staff and postgraduate students across SETU to promote knowledge transfer, enhance research impact, and commercialise research outputs. I provide guidance in developing research and innovation projects, securing funding, creating spin-outs, and building valuable industry partnerships, thereby advancing the practical application and market potential of SETU’s research.
SETU staff and postgraduate students are encouraged to schedule a consultation with me for assistance in identifying new IP assets, determining IP protection strategies, assessing commercialisation potential, and determining optimal commercialisation routes for their research.